Relationship between chronic nasal and respiratory symptoms in patients with COPD  by Roberts, Nicola J et al.
Relationship between chronic nasal and respiratory
symptoms in patients with COPD
Nicola J Roberts, Simon J Lloyd-Owen, Fernando Rapado, Irem S Patel,
Tom MA Wilkinson, Gavin C Donaldson, Jadwiga A Wedzicha*
Academic Unit of Respiratory Medicine, St. Bartholomew’s Hospital and the Royal London School of
Medicine, London EC1A 7BE, UK
Summary The relationship between the upper and lower airways in chronic
obstructive pulmonary disease (COPD) is unknown. We examined the prevalence of
chronic nasal symptoms and the correlation with lower respiratory symptoms and
parameters of severity of COPD such as exacerbation frequency and spirometry. 61
COPD patients from the East London COPD cohort were studied. [Mean (SD) age
70(6.96) years, FEV1 0.98 (0.38) l, FVC 2.45(0.72) l, FEV1%Pred 37.0 (12.3), and 47.6
(31.8) smoking pack years, 14 current smokers, 36 males]. COPD patients had a high
prevalence of nasal symptoms (75%), more than half reporting nasal discharge (52.5%)
and sneezing (45.9%). Associations were found between nasal score and daily sputum
production (P ¼ 0:005) and post-nasal drip and sputum production (P ¼ 0:046) with a
trend to increased nasal symptoms in frequent exacerbators compared to infrequent
exacerbators. No significant relationship was found between nasal symptoms and FEV1
or any other lower respiratory airway symptom. Associations between nasal and
respiratory symptoms were found suggesting that there is a relationship between the
upper and lower airway in COPD.
r 2003 Elsevier Science Ltd. All rights reserved.
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Introduction
The upper and lower airways form one contiguous
and functionally related organ, and are frequently
exposed to similar inflammatory stimuli. There is
increasing interest in the possibility that disease
processes in one part of the airway may be
reflected or manifest in another, thereby providing
opportunities for dual diagnosis and therapy. The
relationship between rhinitis and asthmatic bron-
chial hyperresponsiveness is well recognised.1,2
Studies have shown that up to 88% of asthmatic
patients display symptoms of rhinitis and about 50%
of rhinitic patients experience bronchial hyperre-
sponsiveness.3,4 It has been suggested that upper
respiratory tract disease can lead to or exacerbate
chronic inflammation of the lower airways.5 Chanez
et al.6 has proposed that although changes occur in
both the upper and lower airways when perennial
rhinitis and asthma coexist, the nasal and bronchial
epithelium may behave differently. However, simi-
larities have also been described between bron-
chial and nasal epithelial cells morphologically,
histologically and functionally.7
Cigarette smoking increases lower airways
inflammation as well as affecting the upper
airways.8–10 There is little information on the
long-term effects of cigarette smoking on the
upper airways in patients with chronic obstructive
pulmonary disease (COPD). Up to now, only
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one study has investigated the prevalence of nasal
symptoms in patients classified as having chronic
bronchitis or emphysema. This study found that 40%
of patients had chronic nasal symptoms.11 However,
lung function data was not available and the study
did not examine relationships between upper air-
way symptoms and clinical characteristics of COPD
such as chronic sputum production and exacerba-
tion frequency. The aim of the present study was to
determine the prevalence of nasal symptoms in a
well-characterised group of COPD patients and
study the relationship to lower airway clinical and
physiological parameters in particular the role of
exacerbation frequency.
Methods
Study subjects
Information about the prevalence of nasal symp-
toms was obtained from 61 patients in the East
London COPD study (ELCOPD) cohort with a
diagnosis of moderate-to-severe COPD. COPD was
diagnosed using the BTS guidelines.12 These pa-
tients are part of a rolling cohort of patients with
COPD who have been followed up since October
1995 in the ELCOPD study;13 during this study
period 80 patients were enrolled in the cohort, of
which 61 agreed to take part in this study. The
remaining 19 (24%) from the ELCOPD cohort who
did not participate in the study were not signifi-
cantly different from the 61 patients studied.
[Mean (SD) age 66.6 years (9.79); years in study
1.76 (1.79); FEV1 0.88 (0.39)1; FEV1 (% predicted)
35.4 (11.74); FVC 2.12 (0.83)1; FEV1/FVC 42.6
(11.9); pack years smoked 47.6 (31.8); six current
smokers; years since last smoked 4.3 (8.30)]. COPD
was defined as forced expiratory volume in 1 s
(FEV1) of less than 70% predicted, reversibility to
400 mg of salbutamol via a metered dose inhaler of
less than 15% or 200ml and FEV1/FVC less than
70%.12 Reversibility was assessed on recruitment to
the ELCOPD cohort. Patients with a history of
asthma, bronchiectasis, carcinoma of the bronchus
or other significant respiratory disease were
excluded. Records from the East London COPD
study were used to ascertain smoking history and
exacerbation frequency. Current smoking or past
smoking was assessed by pack years of consumption.
Upper and lower respiratory symptoms
Information was obtained from each patient at
routine clinic visits between May and October 2001
regarding chronic nasal symptoms which they
reported to suffer from when stable. Patients were
asked to report chronic nasal symptoms (symptoms
of chronic rhinitis) experienced on a regular basis
not symptoms experienced during exacerbations.
Five symptoms were assessed, three were obtained
from a definition of rhinitis (symptoms of nasal
discharge, sneezing and nasal congestion)14 and
two clinically important symptoms were added;
decreased sense of smell and post-nasal drip.
Patients were asked if they experienced each of
these symptoms individually and responses were
recorded as an yes or no answer. Post-nasal drip was
described to the patient as a discharge running
down the back of the throat and responses
recorded as an yes or no answer. The five nasal
symptoms were also totalled to produce a nasal
symptom score of between 0 and 5. At the same
visit, patients were also asked whether, when
stable they had daily respiratory symptoms of
shortness of breath, cough sputum and wheeze.
Stable FEV1 and FVC were also recorded at this visit
by rolling seal spirometer (Sensor Medic Corp.,
Yorba Linda, CA, USA). If patients did not undergo
spirometry at this clinic visit spirometry from a
previous clinic visit (within the last 3 months) was
used.
Exacerbation frequencies
Information regarding frequency of exacerbations
experienced by patients was obtained from the
ELCOPD study records. Briefly, patients previously
recorded any increase above their normal respira-
tory symptoms on daily diary cards at 10 a.m. every
morning. Exacerbations were diagnosed according
to our previously validated criteria13,15 as at least 2
days duration of two major symptoms (increase in
dyspnoea, sputum purulence, and increased spu-
tum volume) or one major and one minor symptom
(nasal discharge or nasal blockage, wheeze, sore
throat, cough). Approximately 50% of the exacer-
bations were confirmed at clinic by the study team
within about 48 h of onset. The exacerbation
frequency was defined as the number of exacerba-
tions experienced by each patient during a period
of 18 months prior to completion of the ques-
tionnaire. Frequent exacerbators were defined as
those with an exacerbation frequency greater than
or equal to the median for the entire ELCOPD
cohort (2.55 exacerbations per year); infrequent
exacerbators as less than 2.55 exacerbations per
year. Patients who had not been included in the
cohort for 18 months or more were excluded from
the frequent/infrequent exacerbation analysis.
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Statistical methods
Positive responses were scored as one and negative
as zero. Differences between frequent and infre-
quent exacerbator groups were tested by Mann–
Whitney tests. Chi-squared tests and Spearman’s
rank correlations were used to determine relation-
ships between the chronic nasal symptoms, stable
lower airway symptoms and other clinical para-
meters such as current smoking, FEV1 and FVC. The
computer-based analysis program SPSS (Statistical
Package for Social Science, 10.1 for PC, SPSS Inc,
Chicago IL, USA) was used in all calculations.
Po0:05 was considered to be statistically signifi-
cant.
Results
Information was obtained from 61 COPD patients
(36 men, 25 female) from the ELCOPD cohort. The
patients were assessed at outpatient clinics at the
London Chest Hospital between May and October
2001. Characteristics of these patients are shown in
Table 1.
Prevalence of nasal symptoms
The distribution of the nasal scores and the
prevalence of each symptom are shown in Figs. 1
and 2, respectively. 75.4% of patients had at least
one nasal symptom, more than half of the patients
had two or more symptoms (52.4%) and 39.3% had
three or more symptoms. Nasal discharge was the
most prevalent symptom reported by more than
half of the patients studied (52.5%), compared to
sneezing attacks of which 45.9% of patients
reported, post-nasal drip (39.3%), nasal blockage
(34.4%) and decreased sense of smell (16.7%).
Relationship between nasal and respiratory
symptoms
Table 2 illustrates the median number of nasal
symptoms for patients with and without each
respiratory symptom (sputum production, shortness
of breath, wheeze and cough). Those with sputum
production had a significantly higher number of
total nasal symptoms (P ¼ 0:005). Patients with
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Table 1 Stable patient characteristics.
Age 70 (6.96)
Mean years in study 3.64 (1.91)
FEV1 (l) 0.98 (0.38)
FEV1 (% predicted) 37.0 (12.3)
FVC (l) 2.45 (0.72)
FEV1/FVC (%) 39.69 (12.9)
Reversibility (n ¼ 52) (%) 9.65 (10.8)
Pack years of smoking 47.6 (31.8)
Current smokers (%) 14 (23)
Years since last smoked (ex-smokers)10.1 (11.5)
Mean (SD) characteristics of study group (n ¼ 61 unless
otherwise stated). FEV1=forced expiratory volume in 1 s;
FVC=forced vital capacity.
Figure 1 Frequency of nasal symptoms found in COPD.
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cough also show increased numbers of nasal
symptoms (P ¼ 0:072). There were no significant
relationship trends with the other respiratory
symptoms of breathlessness and wheeze. Those
patients that produced sputum daily were more
likely to have nasal symptoms especially post-nasal
drip (P ¼ 0:046), sneezing attacks (P ¼ 0:008) and a
trend towards nasal discharge (P ¼ 0:081) and nasal
blockage (P ¼ 0:097)
Associations with nasal symptoms
Current smoking or past smoking did not influence
the presence of these self-reported nasal symp-
toms. Current smoking did not increase the
frequency of daily sputum production either (cur-
rent smokers 30%; ex-smokers 28%). The current
and ex-smokers were well matched (smokers 59.2
(SD 39.67), ex-smokers 44.1 (SD 28.69); P ¼ 0:203)
in terms of pack years of cigarettes smoked.
Frequent exacerbators (n ¼ 29) reported a higher
percentage of each nasal symptom compared to
their infrequent counterparts (n ¼ 27), with a
higher median number of symptoms (3 versus 1),
but these differences were not statistically sig-
nificant (nasal blockage, P ¼ 0:140; nasal dis-
charge, P ¼ 0:188; sneezing, P ¼ 0:774; post-nasal
drip, P ¼ 0:379; impaired smell P ¼ 0:506; nasal
score P ¼ 0:195). There was no relationship be-
tween the degree of airflow obstruction as mea-
sured by FEV1 or the FEV1/FVC ratio and the
frequency of nasal symptoms.
Discussion
It is well recognised that there is a strong
association between asthma and nasal conditions
such as allergic rhinitis and rhinosinusitis, with a
similar inflammatory response occurring in both the
upper and lower airways.16,17 Eighty-eight per cent
of asthmatic patients have been shown to have
rhinitis.18 In contrast, although rhinitis is very
common in the general population approximately
one in six people are affected.19 It is not clear,
however, whether the same is found in patients
with COPD. Thus, the objective of this study was to
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Figure 2 Frequency of nasal symptoms found in COPD.
Table 2 Relationship between nasal score and
daily lower respiratory tract symptoms (n ¼ 61)
Daily lower
respiratory
tract symptom
N Median
nasal
score
P value
Sputum Yes 26 3 0.005
No 35 1
Shortness of breath Yes 50 2 0.924
No 11 2
Wheeze Yes 16 1.5 0.953
No 45 2
Cough Yes 29 3 0.072
No 32 1
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investigate the prevalence of nasal symptoms in
COPD patients and relate them to markers of
respiratory disease such as daily symptoms, lung
function and exacerbation frequency.
We found that patients with well-characterised
COPD have a high prevalence of nasal symptoms
(75%), with about half of the patients reporting
nasal discharge and sneezing. There was a strong
association between these nasal symptoms and
daily sputum production, with these patients being
significantly more likely to have symptoms of
sneezing and post-nasal drip and consequently, a
higher nasal symptom score. In addition, there was
a trend for patients with daily cough to have a
higher nasal symptom score compared to those
without cough. There was no significant relation-
ship with the other daily respiratory symptoms of
wheeze and shortness of breath.
Montnemery et al.11 also found an increase in
nasal symptoms in subjects with respiratory dis-
eases: 40% of subjects with self-reported chronic
bronchitis/emphysema had recurrent or permanent
nasal symptoms. However, the severity of the COPD
in these subjects was not assessed. In comparison
our study found nearly double the prevalence of
nasal symptoms with moderate or severe COPD
(mean FEV1 37% predicted). Our study found no
significant relationship between FEV1 and nasal
symptoms or scores.
The inter-relationship between the symptoms of
daily cough, sputum, post-nasal drip and sneezing
in our study may have several explanations. The
same chronic inflammatory process may be occur-
ring in both the nasal and bronchial epithelium with
airway neutrophilia and mucus hypersecretion
leading to increased sputum and nasal secretions.
In addition, the nasal symptoms could be contribut-
ing to the severity of the respiratory symptoms, for
example nasal discharge may be in part, produce
the symptoms of cough. The relationship between
nasal symptoms and sputum production may also in
part be due to some confusion by the patients
between distinguishing post-nasal drip and sputum
production. However, post-nasal drip has been
shown to be a well-recognised cause of cough,
which could also contribute to the volume of
sputum expectorated.
There was little evidence that current smoking
had any direct effect on nasal symptoms and
respiratory symptoms in this study, though this
analysis is limited due to the relatively small
sample size. The current and ex-smokers were well
matched in terms of pack years of smoking. This is
in contrast to other larger epidemiological COPD
studies, which have found significant differences
between ex-smokers and current smokers in re-
spiratory symptoms such as sputum production
after as little as 5 years abstaining from smok-
ing.20–22 In our study, both the smokers and ex-
smokers had relatively high smoking pack year
histories and this may explain the lack of differ-
ences seen between the groups. In addition,
Rutgers et al.23 found that COPD patients who do
not currently smoke still have higher levels of
inflammatory cells compared to age-matched
healthy subjects and this would explain the lack
of interactions between smoking and symptoms in
this study.
In this study, although patients documented as
having frequent exacerbations of their COPD
tended to have more nasal symptoms than those
with infrequent exacerbations, the difference did
not reach statistical significance. Previous work has
shown that frequent exacerbators are more likely
to have symptoms of cough and sputum and
increased airway inflammation.15,24
A significant number of patients with COPD show
evidence of lower airway bacterial colonisation.25
Stockley et al.26 have shown that patients who
expectorate sputum are more likely to be colonised
with bacteria. Our group has shown that COPD
patients with bacterial colonisation have increased
numbers of exacerbations.27 Bacterial colonisation
has been shown to increase sputum production and
airway inflammation in the lower airways, and thus
may also affect the upper respiratory tract produ-
cing more nasal symptoms, as seen in the sputum
producers and frequent exacerbator groups in this
study. Alternatively, the upper airway may serve as
a pool for contamination of the lower airways with
bacteria and inflammatory mediators, contributing
to the airway inflammation in COPD or vice versa.
The importance of inflammatory mediators and
bacteria in the upper respiratory tract and the
effect on the chronic inflammatory process in COPD
is currently unknown.
The high frequency of nasal symptoms in these
patients requires further investigation. Prospective
studies should be undertaken to characterise the
time course of the nasal symptoms in relation to
respiratory ones. Although this study has found a
high frequency of nasal symptoms in this popula-
tion, it is difficult to fully estimate the extent of
these symptoms as a control population was not
used. Further study should consider the prevalence
of chronic nasal symptoms in the same season
(May–October) in different patient types including
controls to adequately assess the increase in
symptoms. However, in this study, there is a
significant increase in nasal symptoms in COPD,
compared to the reported prevalence of rhinitis of
one in six people.19
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In conclusion, nasal symptoms are common in
patients with COPD. Associations between lower
respiratory and nasal symptoms have been found,
suggesting a possible common airway inflammatory
process. Information obtained about upper airways
may be useful in predicting disease processes in the
lower airway. The interaction between inflamma-
tory processes in the upper and lower airways
requires further study.
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